Clinical trial
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
NCT00948142 is registered in ClinicalTrials.gov with Arrevus Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
- Lead sponsor
- Arrevus Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2009
- Completion date
- March 31, 2010
- Enrollment
- 198 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.